In the gut, KPV enters epithelial cells through PepT1 transporters with a Km of roughly 160 uM, among the highest affinities reported for this transporter (Dalmasso et al
Combining bariatric surgery with pharmacologic therapy requires specialized guidance
GIP Receptor (GIPR) Agonism Stimulates robust insulin secretion: GIPR activation enhances glucose-dependent insulin release from pancreatic beta cells, especially effective in the postprandial state 2
Weight loss may plateau or even return
individual results vary significantly Both medications require adherence to dosing schedule and lifestyle modifications Higher doses generally produce better results but may have more side effects Not everyone reaches maximum doses due to side effect tolerance Actual weight loss depends on starting weight, diet, exercise, and individual metabolism Time to See Results: Semaglutide: Weeks 1-4: Minimal weight loss (adjusting to medication) Weeks 4-12: Noticeable appetite reduction and initial weight loss (5-8 pounds) Weeks 12-24: Steady weight loss (1-2 pounds per week) Weeks 24-68: Continued weight loss at slower pace Tirzepatide: Weeks 1-4: Minimal weight loss (adjusting to medication) Weeks 4-12: Noticeable appetite reduction and initial weight loss (8-12 pounds) Weeks 12-24: Steady weight loss (1.5-2.5 pounds per week) Weeks 24-72: Continued weight loss, often at sustained pace Both medications show continued weight loss throughout the clinical trial periods, with weight loss plateauing around month 16-20 for most participants
This means changes must be tracked in the CMC (chemistry, manufacturing, controls) sections of INDs/NDAs, adding a layer of oversight
